Underlying Causes and Treatment Modalities for Neurological Deficits in COVID-19 and Long-COVID

ACS Chem Neurosci. 2022 Oct 19;13(20):2934-2938. doi: 10.1021/acschemneuro.2c00482. Epub 2022 Oct 3.

Abstract

With reports of diverse neurological deficits in the acute phase of COVID-19, there is a surge in neurological findings in Long-COVID─a protracted phase of SARS-CoV-2 infection. Very little is known regarding the pathogenic mechanisms of Neuro-COVID in the above two settings in the current pandemic. Herein, we hint toward the possible molecular mechanism that can contribute to the signs and symptoms of patients with neurological deficits and possible treatment and prevention modalities in the acute and chronic phases of COVID-19.

Keywords: COVID-19; Long-COVID; Neuro-COVID; Neurological Deficits; Post-COVID-19 sequelae; Treatment Long-COVID.

MeSH terms

  • COVID-19*
  • Humans
  • Pandemics
  • Post-Acute COVID-19 Syndrome
  • SARS-CoV-2